• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.

作者信息

Kow Chia Siang, Abdul Sattar Burud Ismail, Hasan Syed Shahzad

机构信息

School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia, School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor, Malaysia.

Department of Surgery, School of Medicine, International Medical University, Kuala Lumpur, Malaysia.

出版信息

Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.

DOI:10.1016/j.mayocp.2021.03.001
PMID:33958065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7934659/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa20/7934659/8c5f380f4e0e/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa20/7934659/8c5f380f4e0e/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa20/7934659/8c5f380f4e0e/gr1_lrg.jpg

相似文献

1
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.法莫替丁的使用与 COVID-19 患者重症病程风险：一项荟萃分析
Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.
2
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.回复——法莫替丁的使用与新冠肺炎患者重症病程风险：一项荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.
3
Famotidine and Mortality in Coronavirus Disease 2019.法莫替丁与2019冠状病毒病死亡率
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
4
Histamine receptors and COVID-19.组胺受体与 COVID-19。
Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18.
5
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?法莫替丁与住院的新冠病毒肺炎患者：益处是真的吗？
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.
6
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.法莫替丁使用与新型冠状病毒肺炎患者临床结局之间的关联：现有证据评估
Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008.
7
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.法莫替丁能否降低新冠病毒肺炎患者进展为重症疾病、死亡及插管的风险？一项系统评价与Meta分析
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
8
Famotidine and Coronavirus Disease 2019.法莫替丁与2019冠状病毒病
Gastroenterology. 2021 Jul;161(1):360-361. doi: 10.1053/j.gastro.2020.12.044. Epub 2020 Dec 30.
9
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.法莫替丁在非住院 COVID-19 患者中的应用及定量症状跟踪：一项病例系列研究。
Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4.
10
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.法莫替丁治疗新冠病毒病的临床疗效无证据：一项系统评价和荟萃分析。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.022. Epub 2022 Dec 1.

引用本文的文献

1
Analyzing Prescribing Trends of Gastric Acid Suppressants in the UK Using Segmented Regression: Evaluating the Influence of COVID-19 (2019-2024).使用分段回归分析英国胃酸抑制剂的处方趋势：评估2019-2024年新冠疫情的影响
Healthcare (Basel). 2025 Feb 20;13(5):442. doi: 10.3390/healthcare13050442.
2
Effectiveness of famotidine on the risk of poor prognosis in patients with COVID-19: A nationwide cohort study in Korea.法莫替丁对新型冠状病毒肺炎患者预后不良风险的有效性：韩国一项全国性队列研究
Heliyon. 2023 Jun;9(6):e16171. doi: 10.1016/j.heliyon.2023.e16171. Epub 2023 Jun 1.
3
Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.

本文引用的文献

1
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.法莫替丁治疗住院 COVID-19 患者的疗效比较。
Am J Gastroenterol. 2021 Apr;116(4):692-699. doi: 10.14309/ajg.0000000000001153.
2
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.质子泵抑制剂或法莫替丁的使用与重症 COVID-19 疾病：一项倾向评分匹配的全地区研究。
Gut. 2021 Oct;70(10):2012-2013. doi: 10.1136/gutjnl-2020-323668. Epub 2020 Dec 4.
3
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.
COVID-19 的胃肠道预防：来自观察性研究中不恰当对照导致严重偏倚的实例。
J Clin Epidemiol. 2022 Nov;151:45-52. doi: 10.1016/j.jclinepi.2022.07.009. Epub 2022 Jul 20.
法莫替丁的使用与30天死亡率无关：一项对来自大型医疗保健系统的7158例2019冠状病毒病住院患者的粗匹配精确研究。
Gastroenterology. 2021 Feb;160(3):919-921.e3. doi: 10.1053/j.gastro.2020.10.011. Epub 2020 Oct 12.
4
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.法莫替丁对 COVID-19 住院患者临床结局的影响。
Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832.
5
Famotidine Against SARS-CoV2: A Hope or Hype?法莫替丁对新型冠状病毒2：希望还是炒作？
Mayo Clin Proc. 2020 Aug;95(8):1797-1799. doi: 10.1016/j.mayocp.2020.05.027. Epub 2020 Jun 6.
6
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.